Literature DB >> 28157214

Differential depth of treatment response required for optimal outcome in patients with blast phase versus chronic phase of chronic myeloid leukemia.

Z Chen1, L J Medeiros1, H M Kantajian2, L Zheng1, Z Gong1, K P Patel1, H Xiong3, W Wang1, J E Cortes2, S Hu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28157214      PMCID： PMC5386338          DOI： 10.1038/bcj.2017.4

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN： 2044-5385            Impact factor:   11.037


× No keyword cloud information.
  15 in total

1.  Haematological cancer: Deep molecular response predicts survival in CML.

Authors:  Mina Razzak
Journal:  Nat Rev Clin Oncol       Date:  2013-12-17       Impact factor: 66.675

Review 2.  A review of the European LeukemiaNet recommendations for the management of CML.

Authors:  Michele Baccarani; Fausto Castagnetti; Gabriele Gugliotta; Gianantonio Rosti
Journal:  Ann Hematol       Date:  2015-03-27       Impact factor: 3.673

3.  Reply to H. Kantarjian et al.

Authors:  Rüdiger Hehlmann; Joerg Hasford; Markus Pfirrmann; Michael Lauseker; Susanne Saußele; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

4.  Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.

Authors:  Hagop Kantarjian; Jorge E Cortes
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

Review 5.  Acute myeloid leukemia: 2014 update on risk-stratification and management.

Authors:  Elihu H Estey
Journal:  Am J Hematol       Date:  2014-11       Impact factor: 10.047

Review 6.  Standardized definitions of molecular response in chronic myeloid leukemia.

Authors:  N C P Cross; H E White; M C Müller; G Saglio; A Hochhaus
Journal:  Leukemia       Date:  2012-04-16       Impact factor: 11.528

7.  Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers.

Authors:  Veronika Rockova; Saman Abbas; Bas J Wouters; Claudia A J Erpelinck; H Berna Beverloo; Ruud Delwel; Wim L J van Putten; Bob Löwenberg; Peter J M Valk
Journal:  Blood       Date:  2011-05-19       Impact factor: 22.113

8.  Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.

Authors:  L Kalmanti; S Saussele; M Lauseker; M C Müller; C T Dietz; L Heinrich; B Hanfstein; U Proetel; A Fabarius; S W Krause; S Rinaldetti; J Dengler; C Falge; E Oppliger-Leibundgut; A Burchert; A Neubauer; L Kanz; F Stegelmann; M Pfreundschuh; K Spiekermann; C Scheid; M Pfirrmann; A Hochhaus; J Hasford; R Hehlmann
Journal:  Leukemia       Date:  2015-02-13       Impact factor: 11.528

9.  Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

Authors:  Rüdiger Hehlmann; Martin C Müller; Michael Lauseker; Benjamin Hanfstein; Alice Fabarius; Annette Schreiber; Ulrike Proetel; Nadine Pletsch; Markus Pfirrmann; Claudia Haferlach; Susanne Schnittger; Hermann Einsele; Jolanta Dengler; Christiane Falge; Lothar Kanz; Andreas Neubauer; Michael Kneba; Frank Stegelmann; Michael Pfreundschuh; Cornelius F Waller; Karsten Spiekermann; Gabriela M Baerlocher; Gerhard Ehninger; Dominik Heim; Hermann Heimpel; Christoph Nerl; Stefan W Krause; Dieter K Hossfeld; Hans-Jochem Kolb; Joerg Hasford; Susanne Saußele; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

10.  Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.

Authors:  Z Chen; J E Cortes; J L Jorgensen; W Wang; C C Yin; M J You; E Jabbour; H M Kantarjian; L J Medeiros; S Hu
Journal:  Leukemia       Date:  2016-02-03       Impact factor: 11.528
View more
  3 in total

Review 1.  Chronic Myeloid Leukemia: Beyond BCR-ABL1.

Authors:  Ting Zhou; L Jeffrey Medeiros; Shimin Hu
Journal:  Curr Hematol Malig Rep       Date:  2018-12       Impact factor: 3.952

Review 2.  Management of Chronic Myeloid Leukemia in Advanced Phase.

Authors:  Massimiliano Bonifacio; Fabio Stagno; Luigi Scaffidi; Mauro Krampera; Francesco Di Raimondo
Journal:  Front Oncol       Date:  2019-10-25       Impact factor: 6.244

Review 3.  Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients.

Authors:  Lulu Wang; Li Li; Rongrong Chen; Xianbo Huang; Xiujin Ye
Journal:  Cancer Manag Res       Date:  2021-06-23       Impact factor: 3.989
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.